Sunday, October 13, 2024 from 4:00 PM to 5:30 PM MST at Convention Center North Building / North Ballroom 120A
Available for 1.50 hours of CPE creditActivity Number: 0217-0000-24-124-L01-PActivity Type: A Knowledge-Based ActivityThe Endocrine and Metabolism PRN Education Committee presents an educational session focused on integrating lifestyle medicine interventions with medication deprescribing in persons with type 2 diabetes (T2D). The session serves as a practical, comprehensive guide to the effective integration of lifestyle medicine principles with medication deprescribing for improved and sustained clinical outcomes in persons with T2D. Specific topics will include a (1) review of guideline recommendations of specific dietary and other lifestyle interventions for persons with T2D; (2) review of clinical trial evidence and the use of specific dietary interventions for achievement of glycemic targets and related clinical outcomes; and (3) best practices in deprescribing and/or safe pharmacologic management for persons with T2D implementing intensive or specific dietary interventions. The target audience includes pharmacists, residents, fellows, and students with an interest in enhancing their knowledge of effective and safe pharmacologic management in the setting of intensive therapeutic lifestyle changes (ITLC). The primary purpose of this session is to educate and summarize practical insights and tools to integrate evidence-based lifestyle medicine interventions with medication deprescribing, contributing to more comprehensive and personalized T2D management.
Learning Objectives1. Discuss the pharmacist’s role in intensive, therapeutic lifestyle changes (ITLC) for type 2 diabetes.
2. Describe guideline recommended ITLC for persons with type 2 diabetes.
3. Summarize available clinical literature of ITLC and intensive lifestyle interventions for achievement of glycemic target and other clinical outcomes in persons with type 2 diabetes.
4. Describe precision ITLC in persons with type 2 diabetes using evidence-based medicine.
5. Review available literature related to best practices in antihyperglycemic deprescribing in the presence of ITLC in persons with type 2 diabetes.
6.Recognize individualized approaches to antihyperglycemic deprescribing with consideration of patient characteristics, preferences, and response to specific ITLC.
| Moderator: | Megan E. Wesling, Pharm.D., BCACP, BCPS | | Interim Chair and Associate Professor in Pharmacotherapy, The University of North Texas Health Science Center at Fort Worth; Director and Clinical Pharmacist – Ambulatory Care, HSC Health Fort Worth, Texas | View Biography |
|
Sweet Liberation: Defeating Diabetes with Lifestyle Interventions4:00 PM to 4:30 PM | Speaker: | Alaina Van Dyke, Pharm.D., MBA, DipACLM, BCACP | | Assistant Professor Texas Tech University School of Pharmacy Dallas, Texas | View Biography |
|
|
Lifestyle Interventions in Type 2 Diabetes: Research Insights and Strategies4:30 PM to 5:00 PM | Speaker: | Sarah A. Kain, Pharm.D., BCACP, TTS | | Manager and Clinical Pharmacy Specialist, Ambulatory Care Community Health Network Indianapolis, Indiana | View Biography |
|
|
Precision Care: Deprescribing Antihyperglycemics in the Setting of Intensive, Therapeutic Lifestyle Interventions in Type 2 Diabetes5:00 PM to 5:30 PM | Speaker: | Nicole Paolini Albanese, Pharm.D., BCACP, CDCES | | Clinical Associate Professor Assistant Dean for Student Success and Engagement University at Buffalo, School of Pharmacy Buffalo, New York | View Biography |
|
|